Share Price and Basic Stock Data
Last Updated: December 10, 2025, 10:25 pm
| PEG Ratio | 2.45 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
TTK Healthcare Ltd, a prominent player in the pharmaceuticals sector, has shown a steady trajectory in its revenue generation. The company’s sales rose from ₹599 Cr in FY 2022 to ₹725 Cr in FY 2023, reflecting a growth rate of approximately 21%. This upward trend continued into FY 2024, with revenues reported at ₹753 Cr, and a trailing twelve-month sales figure of ₹820 Cr, indicating resilience in a challenging market. Despite fluctuations in quarterly sales figures, such as a dip to ₹170 Cr in September 2022, TTK Healthcare rebounded to ₹202 Cr in June 2023. The sales mix, which includes both pharmaceuticals and consumer healthcare products, appears to be a key driver of this performance, showcasing the company’s ability to adapt to market demands.
Profitability and Efficiency Metrics
When examining profitability, TTK Healthcare’s performance reveals a mixed bag. The operating profit margin (OPM) has been relatively modest, standing at 4% for FY 2025. This is a slight decline from previous years, where it peaked at 8% in FY 2023. However, net profit surged dramatically from ₹42 Cr in FY 2022 to ₹640 Cr in FY 2023, largely due to a significant increase in other income, which soared to ₹643 Cr in the same fiscal year. This highlights the importance of non-operational income in bolstering overall profitability. Efficiency metrics such as the cash conversion cycle have shown improvement, rising to 43 days in FY 2025, suggesting that the company is managing its working capital more effectively.
Balance Sheet Strength and Financial Ratios
TTK Healthcare’s balance sheet appears robust, with a market capitalization of ₹1,535 Cr and borrowings limited to ₹27 Cr, reflecting a very low debt-to-equity ratio of 0.02. This conservative leverage strategy positions the company well in terms of financial stability. The interest coverage ratio (ICR) of 31.91x indicates that the company generates ample earnings to cover its interest obligations, suggesting a comfortable financial cushion. Furthermore, with reserves increasing to ₹1,071 Cr, TTK Healthcare has built a solid foundation for future growth initiatives. However, the return on equity (ROE) at 6.89% and return on capital employed (ROCE) at 9.26% point to potential areas for improvement, as these figures are somewhat below industry averages, indicating that the company may not be fully maximizing its capital efficiency.
Shareholding Pattern and Investor Confidence
The shareholding structure of TTK Healthcare reveals a strong promoter confidence, with promoters holding 74.57% of the equity. This level of commitment can be reassuring for retail investors, as it reflects a vested interest in the company’s long-term success. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold relatively minor stakes at 1.90% and 1.18%, respectively, which may indicate a lack of broad institutional interest. However, the public shareholding stands at 22.37%, with the number of shareholders increasing to 16,134, suggesting a growing retail interest in the stock. This mix of ownership could be a double-edged sword; while strong promoter control is a positive, limited institutional backing might raise questions about broader market confidence.
Outlook, Risks, and Final Insight
Looking ahead, TTK Healthcare faces a landscape filled with both opportunities and challenges. The company’s robust revenue growth and strong balance sheet are commendable, yet the declining operating margins raise concerns about cost management and pricing pressures in the pharmaceuticals sector. Competitive dynamics, particularly from generic drug manufacturers and evolving regulatory frameworks, could pose risks to profitability. Additionally, dependence on other income for substantial profit boosts may not be sustainable in the long run. For investors, the stock presents a mixed bag; while the strong promoter backing and financial stability are attractive, the relatively low returns and operational efficiency metrics warrant cautious consideration. Investors should weigh these factors against their risk tolerance and investment horizon before making decisions on TTK Healthcare’s stock.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of TTK Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 239/84.3 | 31.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,177 Cr. | 383 | 479/192 | 86.5 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.4 Cr. | 43.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.3 Cr. | 30.9 | 31.0/17.0 | 108 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,300.00 Cr | 1,152.20 | 52.34 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 193 | 170 | 183 | 180 | 202 | 186 | 184 | 181 | 208 | 198 | 205 | 190 | 226 |
| Expenses | 189 | 166 | 174 | 165 | 192 | 176 | 179 | 169 | 201 | 190 | 197 | 178 | 224 |
| Operating Profit | 4 | 4 | 8 | 15 | 10 | 10 | 5 | 12 | 7 | 8 | 8 | 12 | 3 |
| OPM % | 2% | 2% | 5% | 8% | 5% | 5% | 3% | 7% | 3% | 4% | 4% | 6% | 1% |
| Other Income | 606 | 13 | 12 | 12 | 15 | 16 | 16 | 16 | 37 | 18 | 18 | 13 | 18 |
| Interest | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 604 | 13 | 16 | 23 | 21 | 22 | 18 | 24 | 41 | 23 | 23 | 22 | 18 |
| Tax % | 1% | 23% | 26% | 27% | 24% | 26% | 27% | 25% | 23% | 26% | 26% | 26% | 26% |
| Net Profit | 601 | 10 | 12 | 17 | 16 | 16 | 13 | 18 | 32 | 17 | 17 | 16 | 13 |
| EPS in Rs | 425.23 | 7.01 | 8.49 | 11.99 | 11.09 | 11.33 | 9.12 | 12.93 | 22.35 | 12.17 | 11.84 | 11.43 | 9.20 |
Last Updated: August 20, 2025, 2:00 am
Below is a detailed analysis of the quarterly data for TTK Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 226.00 Cr.. The value appears strong and on an upward trend. It has increased from 190.00 Cr. (Mar 2025) to 226.00 Cr., marking an increase of 36.00 Cr..
- For Expenses, as of Jun 2025, the value is 224.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 178.00 Cr. (Mar 2025) to 224.00 Cr., marking an increase of 46.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 9.00 Cr..
- For OPM %, as of Jun 2025, the value is 1.00%. The value appears to be declining and may need further review. It has decreased from 6.00% (Mar 2025) to 1.00%, marking a decrease of 5.00%.
- For Other Income, as of Jun 2025, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2025) to 18.00 Cr., marking an increase of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 4.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00%.
- For Net Profit, as of Jun 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 16.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 3.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 9.20. The value appears to be declining and may need further review. It has decreased from 11.43 (Mar 2025) to 9.20, marking a decrease of 2.23.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:14 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 416 | 483 | 519 | 528 | 578 | 628 | 646 | 476 | 599 | 725 | 753 | 801 | 820 |
| Expenses | 396 | 453 | 478 | 489 | 535 | 578 | 617 | 457 | 577 | 694 | 715 | 767 | 789 |
| Operating Profit | 20 | 30 | 40 | 38 | 43 | 50 | 28 | 19 | 22 | 31 | 37 | 35 | 31 |
| OPM % | 5% | 6% | 8% | 7% | 7% | 8% | 4% | 4% | 4% | 4% | 5% | 4% | 4% |
| Other Income | 6 | 7 | 6 | 6 | 8 | 8 | 9 | 28 | 42 | 643 | 63 | 85 | 66 |
| Interest | 3 | 4 | 3 | 3 | 5 | 3 | 3 | 2 | 3 | 5 | 3 | 3 | 3 |
| Depreciation | 3 | 6 | 7 | 12 | 15 | 15 | 14 | 13 | 13 | 13 | 13 | 8 | 8 |
| Profit before tax | 20 | 26 | 36 | 29 | 30 | 39 | 19 | 32 | 48 | 657 | 84 | 108 | 85 |
| Tax % | 37% | 39% | 36% | 36% | 40% | 38% | 37% | -44% | 13% | 3% | 25% | 25% | |
| Net Profit | 12 | 16 | 23 | 19 | 18 | 24 | 12 | 46 | 42 | 640 | 63 | 82 | 63 |
| EPS in Rs | 15.95 | 20.81 | 29.19 | 24.13 | 12.86 | 17.25 | 8.72 | 32.87 | 29.43 | 452.72 | 44.47 | 57.79 | 44.64 |
| Dividend Payout % | 25% | 22% | 17% | 21% | 39% | 29% | 34% | 18% | 34% | 2% | 22% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 33.33% | 43.75% | -17.39% | -5.26% | 33.33% | -50.00% | 283.33% | -8.70% | 1423.81% | -90.16% | 30.16% |
| Change in YoY Net Profit Growth (%) | 0.00% | 10.42% | -61.14% | 12.13% | 38.60% | -83.33% | 333.33% | -292.03% | 1432.51% | -1513.97% | 120.31% |
TTK Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 4% |
| 3 Years: | 10% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 42% |
| 3 Years: | 22% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 20% |
| 3 Years: | 9% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 26% |
| 3 Years: | 29% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 4, 2025, 2:08 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 99 | 110 | 128 | 150 | 219 | 237 | 235 | 281 | 316 | 939 | 987 | 1,051 | 1,071 |
| Borrowings | 32 | 42 | 38 | 23 | 47 | 29 | 30 | 19 | 22 | 27 | 23 | 24 | 27 |
| Other Liabilities | 102 | 115 | 128 | 104 | 127 | 136 | 152 | 180 | 207 | 189 | 183 | 192 | 184 |
| Total Liabilities | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,206 | 1,281 | 1,296 |
| Fixed Assets | 54 | 52 | 106 | 99 | 110 | 98 | 89 | 85 | 80 | 71 | 75 | 81 | 78 |
| CWIP | 2 | 46 | 1 | 0 | 1 | 2 | 9 | 0 | 0 | 3 | 1 | 0 | 0 |
| Investments | 0 | 0 | 10 | 9 | 9 | 13 | 9 | 13 | 15 | 13 | 13 | 11 | 12 |
| Other Assets | 184 | 177 | 185 | 177 | 288 | 304 | 325 | 395 | 463 | 1,083 | 1,118 | 1,189 | 1,205 |
| Total Assets | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,206 | 1,281 | 1,296 |
Below is a detailed analysis of the balance sheet data for TTK Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,071.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,051.00 Cr. (Mar 2025) to 1,071.00 Cr., marking an increase of 20.00 Cr..
- For Borrowings, as of Sep 2025, the value is 27.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 24.00 Cr. (Mar 2025) to 27.00 Cr., marking an increase of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 184.00 Cr.. The value appears to be improving (decreasing). It has decreased from 192.00 Cr. (Mar 2025) to 184.00 Cr., marking a decrease of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,296.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,281.00 Cr. (Mar 2025) to 1,296.00 Cr., marking an increase of 15.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 78.00 Cr.. The value appears to be declining and may need further review. It has decreased from 81.00 Cr. (Mar 2025) to 78.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,205.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,189.00 Cr. (Mar 2025) to 1,205.00 Cr., marking an increase of 16.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,296.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,281.00 Cr. (Mar 2025) to 1,296.00 Cr., marking an increase of 15.00 Cr..
Notably, the Reserves (1,071.00 Cr.) exceed the Borrowings (27.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -12.00 | -12.00 | 2.00 | 15.00 | -4.00 | 21.00 | -2.00 | 0.00 | 0.00 | 4.00 | 14.00 | 11.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 34 | 34 | 33 | 24 | 35 | 47 | 43 | 46 | 33 | 46 | 42 | 41 |
| Inventory Days | 64 | 62 | 66 | 65 | 80 | 77 | 101 | 123 | 102 | 89 | 105 | 107 |
| Days Payable | 56 | 50 | 53 | 100 | 130 | 101 | 121 | 170 | 134 | 116 | 110 | 106 |
| Cash Conversion Cycle | 41 | 46 | 46 | -11 | -16 | 22 | 23 | -2 | 1 | 19 | 36 | 43 |
| Working Capital Days | -24 | -31 | -38 | -24 | -30 | -6 | -3 | -32 | -28 | 4 | 49 | 48 |
| ROCE % | 17% | 20% | 23% | 18% | 15% | 15% | 8% | 6% | 8% | 10% | 9% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Axis ELSS Tax Saver Fund | 172,386 | 0.08 | 25.52 | 172,386 | 2025-04-22 15:56:52 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 57.79 | 44.47 | 452.72 | 29.43 | 32.87 |
| Diluted EPS (Rs.) | 57.79 | 44.47 | 452.72 | 29.43 | 32.87 |
| Cash EPS (Rs.) | 63.69 | 53.71 | 461.79 | 38.34 | 42.08 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 750.61 | 705.23 | 671.59 | 230.16 | 205.40 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 753.73 | 708.35 | 674.71 | 233.28 | 208.52 |
| Dividend / Share (Rs.) | 10.00 | 10.00 | 10.00 | 10.00 | 6.00 |
| Revenue From Operations / Share (Rs.) | 567.22 | 532.75 | 513.16 | 424.08 | 336.91 |
| PBDIT / Share (Rs.) | 75.07 | 70.72 | 56.39 | 27.01 | 20.70 |
| PBIT / Share (Rs.) | 69.18 | 61.48 | 47.33 | 18.11 | 11.49 |
| PBT / Share (Rs.) | 76.67 | 59.53 | 43.62 | 17.58 | 16.01 |
| Net Profit / Share (Rs.) | 57.79 | 44.47 | 452.72 | 29.43 | 32.87 |
| PBDIT Margin (%) | 13.23 | 13.27 | 10.98 | 6.36 | 6.14 |
| PBIT Margin (%) | 12.19 | 11.54 | 9.22 | 4.26 | 3.41 |
| PBT Margin (%) | 13.51 | 11.17 | 8.50 | 4.14 | 4.75 |
| Net Profit Margin (%) | 10.18 | 8.34 | 88.22 | 6.94 | 9.75 |
| Return on Networth / Equity (%) | 7.69 | 6.30 | 67.41 | 12.78 | 16.00 |
| Return on Capital Employeed (%) | 9.13 | 8.64 | 6.97 | 7.56 | 5.31 |
| Return On Assets (%) | 6.37 | 5.23 | 54.67 | 7.44 | 9.39 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.02 | 0.06 | 0.06 |
| Asset Turnover Ratio (%) | 0.64 | 0.63 | 0.83 | 1.14 | 1.03 |
| Current Ratio (X) | 5.23 | 5.50 | 5.06 | 2.03 | 1.99 |
| Quick Ratio (X) | 4.72 | 5.01 | 4.66 | 1.68 | 1.61 |
| Inventory Turnover Ratio (X) | 1.90 | 1.91 | 2.23 | 1.92 | 1.38 |
| Dividend Payout Ratio (NP) (%) | 17.30 | 22.48 | 2.20 | 20.38 | 9.12 |
| Dividend Payout Ratio (CP) (%) | 15.70 | 18.61 | 2.16 | 15.65 | 7.12 |
| Earning Retention Ratio (%) | 82.70 | 77.52 | 97.80 | 79.62 | 90.88 |
| Cash Earning Retention Ratio (%) | 84.30 | 81.39 | 97.84 | 84.35 | 92.88 |
| Interest Coverage Ratio (X) | 31.91 | 36.27 | 15.21 | 11.79 | 17.10 |
| Interest Coverage Ratio (Post Tax) (X) | 21.38 | 23.81 | 9.53 | 5.95 | 17.77 |
| Enterprise Value (Cr.) | 926.98 | 1342.13 | 639.44 | 918.42 | 488.79 |
| EV / Net Operating Revenue (X) | 1.16 | 1.78 | 0.88 | 1.53 | 1.03 |
| EV / EBITDA (X) | 8.74 | 13.43 | 8.03 | 24.06 | 16.71 |
| MarketCap / Net Operating Revenue (X) | 2.11 | 2.78 | 2.01 | 1.96 | 1.47 |
| Retention Ratios (%) | 82.69 | 77.51 | 97.79 | 79.61 | 90.87 |
| Price / BV (X) | 1.59 | 2.10 | 1.54 | 3.60 | 2.41 |
| Price / Net Operating Revenue (X) | 2.11 | 2.78 | 2.01 | 1.96 | 1.47 |
| EarningsYield | 0.04 | 0.02 | 0.43 | 0.03 | 0.06 |
After reviewing the key financial ratios for TTK Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 63.69. This value is within the healthy range. It has increased from 53.71 (Mar 24) to 63.69, marking an increase of 9.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 750.61. It has increased from 705.23 (Mar 24) to 750.61, marking an increase of 45.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 753.73. It has increased from 708.35 (Mar 24) to 753.73, marking an increase of 45.38.
- For Dividend / Share (Rs.), as of Mar 25, the value is 10.00. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 567.22. It has increased from 532.75 (Mar 24) to 567.22, marking an increase of 34.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 75.07. This value is within the healthy range. It has increased from 70.72 (Mar 24) to 75.07, marking an increase of 4.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is 69.18. This value is within the healthy range. It has increased from 61.48 (Mar 24) to 69.18, marking an increase of 7.70.
- For PBT / Share (Rs.), as of Mar 25, the value is 76.67. This value is within the healthy range. It has increased from 59.53 (Mar 24) to 76.67, marking an increase of 17.14.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
- For PBDIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 13.27 (Mar 24) to 13.23, marking a decrease of 0.04.
- For PBIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.54 (Mar 24) to 12.19, marking an increase of 0.65.
- For PBT Margin (%), as of Mar 25, the value is 13.51. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 13.51, marking an increase of 2.34.
- For Net Profit Margin (%), as of Mar 25, the value is 10.18. This value exceeds the healthy maximum of 10. It has increased from 8.34 (Mar 24) to 10.18, marking an increase of 1.84.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.69. This value is below the healthy minimum of 15. It has increased from 6.30 (Mar 24) to 7.69, marking an increase of 1.39.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 10. It has increased from 8.64 (Mar 24) to 9.13, marking an increase of 0.49.
- For Return On Assets (%), as of Mar 25, the value is 6.37. This value is within the healthy range. It has increased from 5.23 (Mar 24) to 6.37, marking an increase of 1.14.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.63 (Mar 24) to 0.64, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 5.23. This value exceeds the healthy maximum of 3. It has decreased from 5.50 (Mar 24) to 5.23, marking a decrease of 0.27.
- For Quick Ratio (X), as of Mar 25, the value is 4.72. This value exceeds the healthy maximum of 2. It has decreased from 5.01 (Mar 24) to 4.72, marking a decrease of 0.29.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.90. This value is below the healthy minimum of 4. It has decreased from 1.91 (Mar 24) to 1.90, marking a decrease of 0.01.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 17.30. This value is below the healthy minimum of 20. It has decreased from 22.48 (Mar 24) to 17.30, marking a decrease of 5.18.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 15.70. This value is below the healthy minimum of 20. It has decreased from 18.61 (Mar 24) to 15.70, marking a decrease of 2.91.
- For Earning Retention Ratio (%), as of Mar 25, the value is 82.70. This value exceeds the healthy maximum of 70. It has increased from 77.52 (Mar 24) to 82.70, marking an increase of 5.18.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 84.30. This value exceeds the healthy maximum of 70. It has increased from 81.39 (Mar 24) to 84.30, marking an increase of 2.91.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 31.91. This value is within the healthy range. It has decreased from 36.27 (Mar 24) to 31.91, marking a decrease of 4.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 21.38. This value is within the healthy range. It has decreased from 23.81 (Mar 24) to 21.38, marking a decrease of 2.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 926.98. It has decreased from 1,342.13 (Mar 24) to 926.98, marking a decrease of 415.15.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.16. This value is within the healthy range. It has decreased from 1.78 (Mar 24) to 1.16, marking a decrease of 0.62.
- For EV / EBITDA (X), as of Mar 25, the value is 8.74. This value is within the healthy range. It has decreased from 13.43 (Mar 24) to 8.74, marking a decrease of 4.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.78 (Mar 24) to 2.11, marking a decrease of 0.67.
- For Retention Ratios (%), as of Mar 25, the value is 82.69. This value exceeds the healthy maximum of 70. It has increased from 77.51 (Mar 24) to 82.69, marking an increase of 5.18.
- For Price / BV (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has decreased from 2.10 (Mar 24) to 1.59, marking a decrease of 0.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.78 (Mar 24) to 2.11, marking a decrease of 0.67.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in TTK Healthcare Ltd:
- Net Profit Margin: 10.18%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.13% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.69% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 21.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.72
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.3 (Industry average Stock P/E: 43.06)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.18%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | No 6, Cathedral Road, Chennai (Madras) Tamil Nadu 600086 | info@ttkhealthcare.com http://www.ttkhealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. T T Raghunathan | Executive Chairman |
| Mr. S Kalyanaraman | Managing Director & CEO |
| Mr. K Shankaran | Director |
| Mr. R K Tulshan | Director |
| Dr. T T Mukund | Director |
| Mr. N Ramesh Rajan | Independent Director |
| Mr. V Ranganathan | Independent Director |
| Mr. Murali Neelakantan | Independent Director |
| Mrs. Subashree Anantkrishnan | Independent Director |
| Mrs. Hastha Shivaramakrishnan | Independent Director |
FAQ
What is the intrinsic value of TTK Healthcare Ltd?
TTK Healthcare Ltd's intrinsic value (as of 11 December 2025) is 910.15 which is 14.70% lower the current market price of 1,067.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,504 Cr. market cap, FY2025-2026 high/low of 1,595/991, reserves of ₹1,071 Cr, and liabilities of 1,296 Cr.
What is the Market Cap of TTK Healthcare Ltd?
The Market Cap of TTK Healthcare Ltd is 1,504 Cr..
What is the current Stock Price of TTK Healthcare Ltd as on 11 December 2025?
The current stock price of TTK Healthcare Ltd as on 11 December 2025 is 1,067.
What is the High / Low of TTK Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of TTK Healthcare Ltd stocks is 1,595/991.
What is the Stock P/E of TTK Healthcare Ltd?
The Stock P/E of TTK Healthcare Ltd is 21.3.
What is the Book Value of TTK Healthcare Ltd?
The Book Value of TTK Healthcare Ltd is 768.
What is the Dividend Yield of TTK Healthcare Ltd?
The Dividend Yield of TTK Healthcare Ltd is 0.94 %.
What is the ROCE of TTK Healthcare Ltd?
The ROCE of TTK Healthcare Ltd is 9.26 %.
What is the ROE of TTK Healthcare Ltd?
The ROE of TTK Healthcare Ltd is 6.89 %.
What is the Face Value of TTK Healthcare Ltd?
The Face Value of TTK Healthcare Ltd is 10.0.